phrykt

Oruka Therapeutics, Inc. (ORKA): who owns it and who trades it

As of Nov 16, 2026, ORKA insiders reported 145 open-market sales worth $344M and no purchases in the last 12 months, with 12% of the sale value made under pre-set 10b5-1 plans. The largest seller was Tomas Kiselak (Director), with $300M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Oruka Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ORKA

256 funds and institutions reported ORKA shares worth $7.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
BlackRock, Inc.8.3%
Venrock Adviser, LLC6.9%
Fairmount Funds Management LLC6.1%
Capital World Investors5.6%
Rtw Investments, LP5.2%
State Street Corp4.4%
Vanguard Capital Management LLC3.9%
Paradigm Biocapital Advisors LP3.6%
Deep Track Capital, LP3.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)9.06M15.02%$862M+22%
BlackRock, Inc.4.99M8.27%$475M+41%
Venrock Adviser, LLC4.15M6.88%$395MNo change
Fairmount Funds Management LLC3.71M6.14%$353MNo change
Capital World Investors3.40M5.64%$324M–
Rtw Investments, LP3.14M5.20%$299M+53%
State Street Corp2.67M4.43%$254M+66%
Vanguard Capital Management LLC2.36M3.91%$225M+27%
Paradigm Biocapital Advisors LP2.14M3.56%$204M-8%
Deep Track Capital, LP1.93M3.19%$183M-5%
Bellevue Group AG1.66M2.75%$158M+227%
Franklin Resources Inc1.62M2.69%$154M+61%
Remedium Capital Partners, LLC1.57M2.60%$149MNo change
Ra Capital Management, L.P.1.55M2.58%$148M–
Viking Global Investors LP1.50M2.49%$143M-44%
Geode Capital Management, LLC1.43M2.37%$136M+50%
Jupiter Topco LLC1.38M2.28%$131M–
Perceptive Advisors LLC1.35M2.23%$128M-4%
Polar Capital Holdings Plc1.23M2.04%$117M+17%
Citadel Advisors LLC1.12M1.86%$106M+11%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ORKA insiders reported $0 of open-market purchases and $344M of sales. 12% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$344M
145 trades, 8 people
Sales under a 10b5-1 plan
12%
Share of sale value
Latest trade
Nov 16, 2026
Filed Nov 16, 2026

Purchases and sales by month

$302M$302MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 16, 2026Joana GoncalvesChief Medical OfficerSale plan2,600$99.52$259KForm 4
Nov 16, 2026Joana GoncalvesChief Medical OfficerSale plan1,500$100.48$151KForm 4
Nov 16, 2026Joana GoncalvesChief Medical OfficerSale plan1,900$101.53$193KForm 4
Nov 16, 2026Joana GoncalvesChief Medical OfficerSale plan300$102.47$30.7KForm 4
Nov 16, 2026Joana GoncalvesChief Medical OfficerSale plan200$103.36$20.7KForm 4
Nov 16, 2026Joana GoncalvesChief Medical OfficerSale plan500$105.86$52.9KForm 4
Nov 12, 2026Arjun AgarwalVice presidentSale plan500$101.98$51KForm 4
Nov 12, 2026Arjun AgarwalVice presidentSale plan801$103.16$82.6KForm 4
Nov 12, 2026Arjun AgarwalVice presidentSale plan799$104.25$83.3KForm 4
Nov 12, 2026Arjun AgarwalVice presidentSale plan6,842$105.28$720KForm 4
Nov 12, 2026Arjun AgarwalVice presidentSale plan958$106.18$102KForm 4
Nov 12, 2026Arjun AgarwalVice presidentSale plan100$107.00$10.7KForm 4
Nov 12, 2026Kristine M BallDirectorSale plan1,196$102.10$122KForm 4
Nov 12, 2026Kristine M BallDirectorSale plan1,300$103.09$134KForm 4
Nov 12, 2026Kristine M BallDirectorSale plan2,039$104.16$212KForm 4
Nov 12, 2026Kristine M BallDirectorSale plan10,765$105.31$1.1MForm 4
Nov 12, 2026Kristine M BallDirectorSale plan2,500$106.05$265KForm 4
Nov 12, 2026Kristine M BallDirectorSale plan200$106.98$21.4KForm 4
Nov 2, 2026Lawrence Otto KleinCEOSale plan6,466$94.77$613KForm 4
Nov 2, 2026Lawrence Otto KleinCEOSale plan15,036$95.64$1.4MForm 4
Nov 2, 2026Lawrence Otto KleinCEOSale plan2,442$96.70$236KForm 4
Nov 2, 2026Lawrence Otto KleinCEOSale plan756$97.45$73.7KForm 4
Nov 2, 2026Lawrence Otto KleinCEOSale plan300$98.40$29.5KForm 4
Oct 20, 2026Paul T QuinlanGeneral CounselSale plan400$74.90$30KForm 4
Oct 20, 2026Paul T QuinlanGeneral CounselSale plan500$76.12$38.1KForm 4
Oct 20, 2026Paul T QuinlanGeneral CounselSale plan1,000$77.20$77.2KForm 4
Oct 20, 2026Paul T QuinlanGeneral CounselSale plan4,100$78.79$323KForm 4
Oct 20, 2026Paul T QuinlanGeneral CounselSale plan3,000$79.49$238KForm 4
Oct 15, 2026Joana GoncalvesChief Medical OfficerSale plan2,853$73.89$211KForm 4
Oct 15, 2026Joana GoncalvesChief Medical OfficerSale plan1,847$74.69$138KForm 4
Oct 15, 2026Joana GoncalvesChief Medical OfficerSale plan1,400$75.48$106KForm 4
Oct 15, 2026Joana GoncalvesChief Medical OfficerSale plan700$76.67$53.7KForm 4
Oct 15, 2026Joana GoncalvesChief Medical OfficerSale plan200$77.71$15.5KForm 4
Oct 12, 2026Arjun AgarwalVice presidentSale plan5,741$80.03$459KForm 4
Oct 12, 2026Arjun AgarwalVice presidentSale plan2,100$80.76$170KForm 4
Oct 12, 2026Arjun AgarwalVice presidentSale plan1,958$81.86$160KForm 4
Oct 12, 2026Arjun AgarwalVice presidentSale plan200$82.83$16.6KForm 4
Oct 1, 2026Lawrence Otto KleinCEOSale plan16,246$83.40$1.4MForm 4
Oct 1, 2026Lawrence Otto KleinCEOSale plan8,554$84.03$719KForm 4
Oct 1, 2026Lawrence Otto KleinCEOSale plan200$84.78$17KForm 4
Sep 21, 2026Arjun AgarwalVice presidentSale plan533$95.75$51KForm 4
Sep 21, 2026Paul T QuinlanGeneral CounselSale plan2,900$92.37$268KForm 4
Sep 21, 2026Paul T QuinlanGeneral CounselSale plan2,667$95.31$254KForm 4
Sep 21, 2026Paul T QuinlanGeneral CounselSale plan601$94.44$56.8KForm 4
Sep 21, 2026Paul T QuinlanGeneral CounselSale plan3,832$93.32$358KForm 4
Sep 15, 2026Joana GoncalvesChief Medical OfficerSale plan947$95.71$90.6KForm 4
Sep 15, 2026Joana GoncalvesChief Medical OfficerSale plan1,366$92.99$127KForm 4
Sep 15, 2026Joana GoncalvesChief Medical OfficerSale plan3,150$92.03$290KForm 4
Sep 15, 2026Joana GoncalvesChief Medical OfficerSale plan2,384$91.10$217KForm 4
Sep 15, 2026Joana GoncalvesChief Medical OfficerSale plan100$94.22$9.4KForm 4
Sep 15, 2026Arjun AgarwalVice presidentSale plan560$95.71$53.6KForm 4
Sep 15, 2026Lawrence Otto KleinCEOSale2,452$95.71$235KForm 4
Sep 15, 2026Paul T QuinlanGeneral CounselSale1,039$95.71$99.4KForm 4
Sep 15, 2026Laura Lee SandlerChief Operating OfficerSale906$95.71$86.7KForm 4
Sep 11, 2026Arjun AgarwalVice presidentSale plan3,000$91.11$273KForm 4
Sep 11, 2026Arjun AgarwalVice presidentSale plan4,051$92.41$374KForm 4
Sep 11, 2026Arjun AgarwalVice presidentSale plan2,208$93.26$206KForm 4
Sep 11, 2026Arjun AgarwalVice presidentSale plan200$94.02$18.8KForm 4
Sep 1, 2026Laura Lee SandlerChief Operating OfficerSale plan4,000$92.01$368KForm 4
Sep 1, 2026Laura Lee SandlerChief Operating OfficerSale plan1,000$91.05$91KForm 4
Sep 1, 2026Lawrence Otto KleinCEOSale plan4,800$92.44$444KForm 4
Sep 1, 2026Lawrence Otto KleinCEOSale plan63,596$91.90$5.8MForm 4
Sep 1, 2026Lawrence Otto KleinCEOSale plan6,604$90.79$600KForm 4
Aug 17, 2026Joana GoncalvesChief Medical OfficerSale plan300$110.52$33.2KForm 4
Aug 17, 2026Joana GoncalvesChief Medical OfficerSale plan900$109.65$98.7KForm 4
Aug 17, 2026Joana GoncalvesChief Medical OfficerSale plan2,480$112.56$279KForm 4
Aug 17, 2026Joana GoncalvesChief Medical OfficerSale plan3,320$112.01$372KForm 4
Aug 14, 2026Paul T QuinlanGeneral CounselSale plan3,847$111.14$428KForm 4
Aug 14, 2026Paul T QuinlanGeneral CounselSale plan9,193$110.00$1MForm 4
Aug 14, 2026Paul T QuinlanGeneral CounselSale plan10,200$109.11$1.1MForm 4
Aug 14, 2026Paul T QuinlanGeneral CounselSale plan14,696$107.97$1.6MForm 4
Aug 14, 2026Paul T QuinlanGeneral CounselSale plan10,434$107.14$1.1MForm 4
Aug 14, 2026Paul T QuinlanGeneral CounselSale plan3,630$106.05$385KForm 4
Aug 13, 2026Arjun AgarwalVice presidentSale plan2,100$104.67$220KForm 4
Aug 13, 2026Arjun AgarwalVice presidentSale plan2,358$108.46$256KForm 4
Aug 13, 2026Arjun AgarwalVice presidentSale plan2,142$107.71$231KForm 4
Aug 13, 2026Arjun AgarwalVice presidentSale plan2,132$105.57$225KForm 4
Aug 13, 2026Arjun AgarwalVice presidentSale plan1,268$106.63$135KForm 4
Jul 15, 2026Joana GoncalvesChief Medical OfficerSale plan300$87.25$26.2KForm 4
Jul 15, 2026Joana GoncalvesChief Medical OfficerSale plan400$84.37$33.7KForm 4
Jul 15, 2026Joana GoncalvesChief Medical OfficerSale plan2,497$85.86$214KForm 4
Jul 15, 2026Joana GoncalvesChief Medical OfficerSale plan3,803$86.68$330KForm 4
Jul 13, 2026Arjun AgarwalVice presidentSale plan300$85.63$25.7KForm 4
Jul 13, 2026Arjun AgarwalVice presidentSale plan3,743$84.26$315KForm 4
Jul 13, 2026Arjun AgarwalVice presidentSale plan5,656$84.90$480KForm 4
Jul 13, 2026Arjun AgarwalVice presidentSale plan300$83.07$24.9KForm 4
Jul 1, 2026Tomas Kiselak +4DirectorSale3.55M$84.43$300MForm 4
Jul 1, 2026Laura Lee SandlerChief Operating OfficerSale plan500$95.47$47.7KForm 4
Jul 1, 2026Laura Lee SandlerChief Operating OfficerSale plan2,263$94.75$214KForm 4
Jul 1, 2026Laura Lee SandlerChief Operating OfficerSale plan2,237$93.85$210KForm 4
Jun 22, 2026Arjun AgarwalVice presidentSale plan888$80.01$71KForm 4
Jun 22, 2026Arjun AgarwalVice presidentSale plan699$82.15$57.4KForm 4
Jun 15, 2026Arjun AgarwalVice presidentSale plan395$69.69$27.5KForm 4
Jun 15, 2026Joana GoncalvesChief Medical OfficerSale plan947$69.69$66KForm 4
Jun 15, 2026Joana GoncalvesChief Medical OfficerSale plan5,064$69.42$352KForm 4
Jun 15, 2026Joana GoncalvesChief Medical OfficerSale plan300$70.62$21.2KForm 4
Jun 15, 2026Joana GoncalvesChief Medical OfficerSale plan1,636$68.38$112KForm 4
Jun 15, 2026Lawrence Otto KleinCEOSale1,729$69.69$120KForm 4
Jun 15, 2026Laura Lee SandlerChief Operating OfficerSale600$69.69$41.8KForm 4
Jun 15, 2026Paul T QuinlanGeneral CounselSale733$69.69$51.1KForm 4

Latest 100 of 145 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Tomas KiselakDirector, 10% owner–$300MJul 1, 2026
Lawrence Otto KleinChief Executive Officer, Director–$11.8MNov 2, 2026
Carl DambkowskiDirector–$8.6MJun 12, 2026
Paul T QuinlanGeneral Counsel–$7.5MOct 20, 2026
Arjun AgarwalSenior Vice President, Finance–$6.2MNov 12, 2026
Joana GoncalvesChief Medical Officer–$5.8MNov 16, 2026
Laura Lee SandlerChief Operating Officer–$1.9MSep 15, 2026
Kristine M BallDirector–$1.9MNov 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ORKA short interest

Moderate short interest. 9.8% of ORKA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 3%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.46M ORKA shares were sold short, 9.8% of the shares outstanding, up 5.8% from the report before. At the average daily volume of 915,065 shares, buying them all back would take about 7.1 trading days (days to cover).

Shares short, % of all shares

9.76%May 15Oct 3016.1%

Days to cover

7.1May 15Oct 3012.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.46M9.76%+6%915,0657.1
Oct 15, 20266.11M9.23%-21%841,4067.3
Sep 30, 20267.78M11.75%+2%1.23M6.3
Sep 15, 20267.62M11.51%-2%656,68611.6
Aug 31, 20267.79M11.77%-6%840,4759.3
Aug 14, 20268.30M12.54%+3%732,73611.3
Jul 31, 20268.05M12.16%-9%961,1648.4
Jul 15, 20268.83M14.65%-4%1.42M6.2
Jun 30, 20269.16M15.19%+33%2.14M4.3
Jun 15, 20266.90M11.44%+8%1.13M6.1
May 29, 20266.37M10.57%+2%1.28M5.0
May 15, 20266.25M10.37%-11%1.75M3.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Oruka Therapeutics company events

Oruka Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 26, 2026.

  1. Oct 26, 2026AnnouncementOruka announced Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-B Phase 2b Key 16-Week Results EVERLAST-B is a randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating the safety, efficacy and… Filing
  2. Aug 24, 2026LeadershipOruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards commenced employment as Chief Commercial Officer on August 24, 2026. Filing
  3. Aug 10, 2026ResultsReleased financial results. Filing
  4. Jun 4, 2026VoteReported shareholder vote results. Filing
  5. Jun 1, 2026AnnouncementOruka Therapeutics, Inc. entered into the First Amendment to IL-23 License Agreement, amending the IL-23 License Agreement dated as of December 17, 2024, by and between the Company and Paragon Therapeutics, Inc. Filing
  6. Apr 30, 2026AnnouncementThe Company entered into an Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters named in Schedule A thereto, providing for the… Filing
  7. Apr 27, 2026AnnouncementOruka announced results from its Phase 2a EVERLAST-A clinical trial of ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-A Phase 2a Key 16-Week Results The Phase 2a EVERLAST-A clinical trial is a randomized, double-blind, placebo-controlled study evaluating ORKA-001 in patients with… Filing
  8. Dec 11, 2025LeadershipCameron Turtle resigned as a member of the Board of Directors of Oruka Therapeutics, Inc. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Oruka Therapeutics financials

Famous investors that hold ORKA

5 of the 50 well-known investors we track reported holding ORKA in their latest 13F filing. The largest position is Steve Cohen's, worth $31.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026373,455$31.1M0.1%New
Ken Fisher · Fisher Asset ManagementQ3 2026215,593$18M0.0%+218%
Israel Englander · Millennium ManagementQ3 2026158,558$13.2M0.0%+382%
Andreas Halvorsen · Viking Global InvestorsQ3 202658,000$4.8M0.0%-96%
Ken Griffin · Citadel AdvisorsQ3 20265,528$460K0.0%-100%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ORKA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G6.6%
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G6.6%
Nov 16, 2026RTW Investments, LP13G/A4.7%
Nov 16, 2026RTW Investments, LP13G/A4.7%

Questions about Oruka Therapeutics, Inc. (ORKA) stock

Who owns the most ORKA stock?

The largest reported owner of Oruka Therapeutics, Inc. (ORKA) is FMR LLC (Fidelity), with 15.0% of the company. In total, 256 funds and institutions reported holding ORKA at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are ORKA insiders buying or selling?

In the last 12 months, ORKA insiders reported no open-market purchases and 145 sales worth $344M. The latest trade was on Nov 16, 2026. See every trade.

What is the short interest in ORKA?

As of Oct 30, 2026, 6.46M ORKA shares were sold short, 9.8% of the shares outstanding, up 5.8% from the report before. At the average daily volume of 915,065 shares, buying them all back would take about 7.1 trading days (days to cover). See the history.

Which famous investors hold ORKA?

5 of the 50 well-known investors we track reported ORKA in their latest 13F filing, including Steve Cohen, Ken Fisher, Israel Englander. The largest position is worth $31.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.